Bridging the gap: Integrating oxidative stress profiling with retinal imaging for precision management of diabetic retinopathy.

Diabetic retinopathy (DR) remains a primary cause of vision impairment in working-age adults, driven by chronic hyperglycemia-induced oxidative stress that exacerbates retinal microvascular alterations, including pericyte loss, endothelial dysfunction, and capillary occlusion. This narrative review summarizes evidence suggesting that specific oxidative signatures may precede detectable microvascular alterations, suggesting a "metabolic-memory" imprint on retinal cellular homeostasis. This paradigm shift implicates oxidative stress biomarkers not merely as correlates of disease but as predictive tools for stratifying patients at risk of progression from non-proliferative to proliferative DR. This review examines current laboratory evidence on oxidative stress markers, such as malondialdehyde (MDA), 8-isoprostanes, superoxide dismutase (SOD), glutathione (GSH), and total antioxidant capacity (TAC), in relation to DR pathogenesis and progression. Drawing on epidemiological and clinical studies, we elucidate how elevated lipid peroxidation products (e.g., MDA and 8-isoprostanes) correlate with early microvascular changes and disease severity, while diminished antioxidant enzymes (e.g., SOD and GSH) reflect systemic redox imbalance, potentially serving as prognostic indicators of transitions from non-proliferative to proliferative DR. Innovatively, we propose an integrated biomarker panel combining these oxidative indices with advanced retinal imaging modalities, such as optical coherence tomography angiography, to enhance early detection sensitivity. Furthermore, emerging interventions targeting oxidative pathways, including carotenoid antioxidants like zeaxanthin and novel nanotechnology-based delivery systems for SOD mimetics, offer promising avenues for halting microvascular degeneration. By bridging laboratory assays with clinical translation, this review underscores the potential value of routine oxidative stress profiling in diabetic patients to support timely, biomarker-guided adjunctive interventions, ultimately mitigating DR-related morbidity and improving clinical risk stratification in ophthalmology.